Patients with castration-resistant prostate cancer (CRPC) who are at high risk for developing metastasis may safely add Erleada (apalutamide) to androgen deprivation therapy without worrying about their quality of life, a new study shows. In February, the treatment became the first androgen receptor inhibitor approved in the United States for non-metastatic CRPC, and additional analysis from the SPARTAN Phase 3 trial (NCT01946204) shows that quality of life is not affected. The findings were published in The Lancet Oncology, in a study titled "Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial." "Prostate cancer treatment can often result in unwelcome side effects that can impact or disrupt patients' everyday lives," Fred Saad, MD, a SPARTAN investigator and author of the study, said in a press release. "As clinicians, we want to monitor and measure the impact of new treatments to see if there is an effect on patients' overall health and well-being," added Saad, who also is a professor and chairman of urology at the University of Montreal Hospital Center. "The fact that a treatment such as apalutamide can be added to current standard of care, prolonging metastasis-free survival without significantly impacting HRQoL [health-related quality of life], is a significant advance for patients with nmCRPC and for clinicians who treat them." SPARTAN included 1,207 patients with non-metastatic CRPC whose PSA levels were rapidly increasing while on androgen deprivation therapy. In the trial, patients kept receiving androgen deprivation therapy, and were randomly assigned Janssen Oncology's Erleada or a placebo.